ORbital-Atherektomie zur Läsionsvorbereitung bei Patienten mit chronisch kritischer Extremitätenischämie (ORACLE)
ORbital-Atherektomie zur Läsionsvorbereitung bei Patienten mit chronisch-limb-bedrohender Ischämie
ORACLE is a Europe-wide study that will follow 250 people with critical limb-threatening ischemia (CLTI). It aims to see how well orbital atherectomy (OA) works in real-life practice. OA is a procedure that uses a tiny spinning tool to gently remove hard calcium from inside an artery, helping to open the vessel so other treatments-like balloons or stents-can work better. The study focuses on people who have heavily calcified arteries in the femoropopliteal or infrapopliteal areas of the leg.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Claire Poulet, PhD
- Telefonnummer: +41 79 385 16 78
- E-Mail: oracue@cirse.org
Studieren Sie die Kontaktsicherung
- Name: Dhwani S. Korde, PhD
- Telefonnummer: +4367762942469
- E-Mail: oracue@cirse.org
Studienorte
-
-
-
Hull, Vereinigtes Königreich, HU3 2JZ
- Rekrutierung
- Hull University Teaching Hospitals NHS Trust
-
Hauptermittler:
- Raghu Lakshminarayan, Dr
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Adult CLTI patients with femoropopliteal or infrapopliteal calcified lesions treated with OA using the Stealth 360 Peripheral OA System for vessel preparation prior to any adjunctive endovascular procedure.
Beschreibung
Inclusion Criteria:
- Rutherford classification category ≥4;
- Treatment of femoropopliteal or infrapopliteal calcified lesions with OA using the Stealth 360 peripheral OA System;
- Calcification of target lesions must be visible on fluoroscopy or CT-angiography;
- Patients competent and willing to provide informed consent.
Exclusion Criteria:
- Minors and other vulnerable populations who may not be able to give informed consent freely or for whom participation is not essential to the study (incapacitated and unconscious individuals, persons deprived of liberty, pregnant and breastfeeding women, etc.);
- Inadequate inflow (>30% stenosis) following optimization;
- Insufficient direct outflow (less than 1 run-off vessel);
- Endovascular procedure(s) on the treatment site within 4 weeks before index procedure;
- Patients planned to receive an above ankle amputation of the target limb;
- Patients enrolled in RESCUE (ClinicalTrials.gov ID NCT07270575).
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Beobachtungsmodelle: COHORT
- Zeitperspektiven: PROSPECTIVE
Anzahl der Gruppen / Kohorten
Kohorten und Interventionen
Gruppe / KohorteGruppe / Kohorte |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Adult CLTI patients with femoropopliteal or infrapopliteal calcified lesions
Eligible patients are those who will undergo OA prior to any adjunctive endovascular procedure |
The Stealth 360™ Peripheral Orbital Atherectomy System uses a diamond-coated, eccentrically mounted crown with bi-directional capabilities that treat a wide range of vessels, enabling single device treatment of multiple lesions and vessel sizes.
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Number of lesions with ≤30% residual stenosis after completion of full planned procedure
Zeitfenster: Immediately after procedure completion
|
Defined as residual stenosis ≤30%, immediately after completion of full planned procedure (OA + any planned adjunctive intervention(s)). |
Immediately after procedure completion
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Number of lesions with ≤30% residual stenosis after any unplanned endovascular intervention(s)
Zeitfenster: Immediately after procedure completion
|
Defined as residual stenosis ≤30% immediately after completion of additional unplanned endovascular intervention(s) (any endovascular procedure that was not part of the primary procedure plan). |
Immediately after procedure completion
|
|
Need for unplanned bailout stenting
Zeitfenster: Immediately after procedure completion
|
Defined as any stent placement that was not part of the primary procedure plan. |
Immediately after procedure completion
|
|
Number of participants free from Clinically-Driven Target Lesion Revascularization (CD-TLR)
Zeitfenster: 12 and 24 months
|
Defined as freedom from any endovascular re-intervention to the target lesion (± 10 mm) or surgical bypass performed because of restenosis or occlusion of the target lesion. |
12 and 24 months
|
|
CD-TLR-free survival
Zeitfenster: Until the end of the follow-up period of 2 years
|
Defined as time between first OA procedure and any endovascular re-intervention to the target lesion (± 10 mm) or surgical bypass performed because of restenosis or occlusion of the target lesion. |
Until the end of the follow-up period of 2 years
|
|
Clinical response using Rutherford classification categories
Zeitfenster: 12 and 24 months
|
The Rutherford classification is a clinical scale used to categorize the severity of peripheral arterial disease: Category 0 = asymptomatic; Category 1 = mild claudication; Category 2 = moderate claudication; Category 3 = severe claudication; Category 4 = ischemic rest pain; Category 5 = minor tissue loss; Category 6 = severe tissue loss. |
12 and 24 months
|
|
Wound status
Zeitfenster: 12 and 24 months
|
Defined as healing status of the dominant ischemic wound of the target limb (complete, partial, unchanged, worsening). |
12 and 24 months
|
|
Freedom from amputation of the target limb
Zeitfenster: 12 and 24 months
|
Defined as absence of any amputation of the target limb (above ankle). |
12 and 24 months
|
|
Amputation-free survival
Zeitfenster: Until the end of the follow-up period of 2 years
|
Defined as time between first OA procedure and above-ankle amputation of the target limb. |
Until the end of the follow-up period of 2 years
|
|
Overall survival
Zeitfenster: Until the end of the follow-up period of 2 years
|
Defined as the time between the first OA procedure and death of any cause. |
Until the end of the follow-up period of 2 years
|
|
Patient-reported health-related quality-of-life
Zeitfenster: Baseline, 6, 12 and 24 months post treatment
|
Measured by Vascular Quality of Life Questionnaire - 6 items (VascuQol-6), which is a short patient-reported outcome measure (PROM), used to assess health-related quality of life in people with PAD. It consists of 6 questions, each scored from 1 to 7, with 1 as the worst possible quality of life and 7 as the best possible quality of life. Higher overall scores reflect better quality of life for patients with PAD. |
Baseline, 6, 12 and 24 months post treatment
|
|
Frequency and severity of procedural complications and other adverse events
Zeitfenster: Within 30 days after the OA procedure
|
Grading according to the classification system of the Cardiovascular and Interventional Radiological Society of Europe. |
Within 30 days after the OA procedure
|
|
Clinical response using ankle-brachial index (ABI)
Zeitfenster: 12 and 24 months
|
The ankle-brachial index (ABI) is a non-invasive measure calculated as the ratio of systolic blood pressure at the ankle to systolic blood pressure at the arm. ABI categories commonly used to classify peripheral arterial disease are: >1.40 = non-compressible arteries; 1.00-1.40 = normal; 0.91-0.99 = borderline; 0.41-0.90 = mild to moderate peripheral arterial disease; <0.40 = severe peripheral arterial disease. |
12 and 24 months
|
|
Clinical response using toe pressure
Zeitfenster: 12 and 24 months
|
The toe pressure test measures distal limb perfusion by recording systolic pressure at the toe. In CLTI patients, toe pressure ≤30 mmHg is commonly used to indicate severe ischemia, while values >30 mmHg suggest better perfusion. |
12 and 24 months
|
|
Clinical response using WIfi (wound, ischemia and foot infection) score
Zeitfenster: 12 and 24 months
|
The WIfI classification is a staging system used to assess CLTI based on wound extent, ischemia severity, and foot infection. Each component is graded from 0 (none) to 3 (severe). Lower WIfI scores indicate a lower risk of limb loss and a lesser urgency for revascularization, whereas higher scores indicate greater disease severity, higher amputation risk, and greater potential benefit from revascularization. |
12 and 24 months
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Mitarbeiter
Mitarbeiter
Ermittler
Ermittler
- Studienstuhl: Gerd Grözinger, Prof. Dr. med., SLK Kliniken Heilbronn GmbH
- Studienstuhl: Marianne Brodmann, Univ.-Prof. Dr. med., Medizinische Universität Graz
- Studienstuhl: Stefan Müller-Hülsbeck, Prof. Dr. med., DIAKO Krankenhaus gGmBH
- Studienstuhl: Raghu Lakshminarayan, Dr, Hull University Teaching Hospitals NHS Trust
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Nordanstig J, Wann-Hansson C, Karlsson J, Lundstrom M, Pettersson M, Morgan MB. Vascular Quality of Life Questionnaire-6 facilitates health-related quality of life assessment in peripheral arterial disease. J Vasc Surg. 2014 Mar;59(3):700-7. doi: 10.1016/j.jvs.2013.08.099. Epub 2013 Dec 15.
- Filippiadis DK, Binkert C, Pellerin O, Hoffmann RT, Krajina A, Pereira PL. Cirse Quality Assurance Document and Standards for Classification of Complications: The Cirse Classification System. Cardiovasc Intervent Radiol. 2017 Aug;40(8):1141-1146. doi: 10.1007/s00270-017-1703-4. Epub 2017 Jun 5.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
- Periphere arterielle Verschlusskrankheit
- OA
- CLTI
- Chronische Extremitätenischämie
- Infrapopliteale Arterien
- Beobachtende Kohortenstudie
- Orbitale Atherektomie
- Schiffsvorbereitung
- Verkalkte periphere Arterienläsionen
- Kritische, extremitätenbedrohende Ischämie
- Femoropopliteale Arterien
- Atherektomie für verkalkte Läsionen
Zusätzliche relevante MeSH-Bedingungen
- Gefäßerkrankungen
- Herz-Kreislauf-Erkrankungen
- Pathologische Prozesse
- Chronische Erkrankung
- Krankheitsattribute
- Atherosklerose
- Arteriosklerose
- Arterielle Verschlusskrankheiten
- Periphere Gefäßerkrankungen
- Ischämie
- Pathologische Zustände, Anzeichen und Symptome
- Chronische, die Gliedmaßen bedrohende Ischämie
- Periphere arterielle Verschlusskrankheit
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- ORACLE
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .